GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroPace Inc (NAS:NPCE) » Definitions » Piotroski F-Score

NeuroPace (NeuroPace) Piotroski F-Score : 4 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeuroPace Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuroPace has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for NeuroPace's Piotroski F-Score or its related term are showing as below:

NPCE' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 4

During the past 5 years, the highest Piotroski F-Score of NeuroPace was 5. The lowest was 2. And the median was 4.


NeuroPace Piotroski F-Score Historical Data

The historical data trend for NeuroPace's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroPace Piotroski F-Score Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 5.00 2.00 4.00

NeuroPace Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 3.00 4.00

Competitive Comparison of NeuroPace's Piotroski F-Score

For the Medical Devices subindustry, NeuroPace's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroPace's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NeuroPace's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -10.375 + -9.124 + -7.257 + -6.2 = $-32.96 Mil.
Cash Flow from Operations was -9.698 + -4.36 + -2.302 + -3.341 = $-19.70 Mil.
Revenue was 14.472 + 16.51 + 16.427 + 18.012 = $65.42 Mil.
Gross Profit was 10.372 + 11.972 + 12.233 + 13.545 = $48.12 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(114.106 + 106.271 + 102.232 + 99.3 + 107.651) / 5 = $105.912 Mil.
Total Assets at the begining of this year (Dec22) was $114.11 Mil.
Long-Term Debt & Capital Lease Obligation was $70.77 Mil.
Total Current Assets was $92.72 Mil.
Total Current Liabilities was $16.23 Mil.
Net Income was -11.461 + -12.69 + -11.785 + -11.146 = $-47.08 Mil.

Revenue was 11.374 + 10.2 + 11.157 + 12.789 = $45.52 Mil.
Gross Profit was 8.259 + 7.466 + 7.965 + 8.803 = $32.49 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(133.562 + 128.982 + 118.544 + 120.474 + 114.106) / 5 = $123.1336 Mil.
Total Assets at the begining of last year (Dec21) was $133.56 Mil.
Long-Term Debt & Capital Lease Obligation was $68.35 Mil.
Total Current Assets was $97.71 Mil.
Total Current Liabilities was $10.98 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuroPace's current Net Income (TTM) was -32.96. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuroPace's current Cash Flow from Operations (TTM) was -19.70. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-32.956/114.106
=-0.28881917

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-47.082/133.562
=-0.35251044

NeuroPace's return on assets of this year was -0.28881917. NeuroPace's return on assets of last year was -0.35251044. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NeuroPace's current Net Income (TTM) was -32.96. NeuroPace's current Cash Flow from Operations (TTM) was -19.70. ==> -19.70 > -32.96 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=70.768/105.912
=0.66817735

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=68.353/123.1336
=0.5551125

NeuroPace's gearing of this year was 0.66817735. NeuroPace's gearing of last year was 0.5551125. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=92.719/16.229
=5.71316779

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=97.714/10.976
=8.90251458

NeuroPace's current ratio of this year was 5.71316779. NeuroPace's current ratio of last year was 8.90251458. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NeuroPace's number of shares in issue this year was 26.81. NeuroPace's number of shares in issue last year was 24.835. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=48.122/65.421
=0.7355742

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=32.493/45.52
=0.7138181

NeuroPace's gross margin of this year was 0.7355742. NeuroPace's gross margin of last year was 0.7138181. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=65.421/114.106
=0.57333532

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=45.52/133.562
=0.3408155

NeuroPace's asset turnover of this year was 0.57333532. NeuroPace's asset turnover of last year was 0.3408155. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuroPace has an F-score of 4 indicating the company's financial situation is typical for a stable company.

NeuroPace  (NAS:NPCE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NeuroPace Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of NeuroPace's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroPace (NeuroPace) Business Description

Traded in Other Exchanges
N/A
Address
455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Executives
Martha Morrell officer: Chief Medical officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Kck Ltd. 10 percent owner CRAIGMUIR CHAMBERS, ROAD TOWN, TORTOLA D8 VG1110
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Joel Becker director, officer: Chief Executive Officer ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Uri Geiger director 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
Irina Ridley officer: General Counsel and Secretary C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Lisa Andrade director 6300 BEE CAVE ROAD, BLDG 2, SUITE 100, AUSTIN TX 78746
Greg Shaw Garfield director C/O SEMLER SCIENTIFIC, INC., 2330 NW EVERETT ST., PORTLAND OR 97210
Frank M Fischer director 9701 JERONIMO, IRVINE CA 92618
Evan Norton director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Joseph Lacob director 2820 ORCHARD PARKWAY, SAN JOSE CA 95131
Renee Ryan director C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043
Michael Favet director, officer: Chief Executive Officer C/O NEUROPACE INC, 455 N. BERNARDO AVENUE, MOUTAIN VIEW CA 94043